Patents by Inventor Sven Lindemann
Sven Lindemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813307Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: GrantFiled: June 4, 2018Date of Patent: November 14, 2023Assignees: MERCK PATENT GMBH, ABLYNX NVInventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
-
Publication number: 20220289860Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: ApplicationFiled: January 19, 2022Publication date: September 15, 2022Inventors: Marie-Ange Buyse, Guy Hermans, Sven Lindemann, Hans Guehring, Ralf Guenther, Roland Kellner
-
Patent number: 11261260Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: GrantFiled: June 4, 2018Date of Patent: March 1, 2022Assignees: Merck Patent GmbH, ABLYNX NVInventors: Marie-Ange Buyse, Guy Hermans, Sven Lindemann, Hans Guehring, Ralf Guenther, Roland Kellner
-
Publication number: 20210008160Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: ApplicationFiled: June 4, 2018Publication date: January 14, 2021Applicants: Merck Patent GmbH, ABLYNX NVInventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
-
Publication number: 20200317802Abstract: The present invention relates to immunoglobulins that bind ADAMTSS and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: ApplicationFiled: June 4, 2018Publication date: October 8, 2020Applicants: Merck Patent GmbH, ABLYNX NVInventors: Marie-Ange BUYSE, Guy HERMANS, Sven LINDEMANN, Hans GUEHRING, Ralf GUENTHER, Roland KELLNER
-
Publication number: 20170348380Abstract: The present invention relates to pharmaceutical preparations and medicaments for intraarticular administration, comprising pepstatin, and to the preparation and use thereof, in particular in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia, particularly preferably in arthrosis.Type: ApplicationFiled: June 16, 2017Publication date: December 7, 2017Applicant: Merck Patent GmbHInventors: Markus KLEIN, Ralf WODOPIA, Hans GUEHRING, Sven LINDEMANN
-
Patent number: 9750784Abstract: The present invention relates to pharmaceutical preparations and medicaments for intraarticular administration, comprising pepstatin, and to the preparation and use thereof, in particular in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia, particularly preferably in arthrosis.Type: GrantFiled: July 7, 2014Date of Patent: September 5, 2017Assignee: MERCK PATENT GMBHInventors: Markus Klein, Ralf Wodopia, Hans Guehring, Sven Lindemann
-
Patent number: 9656949Abstract: The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which ADAMTS5 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.Type: GrantFiled: January 16, 2014Date of Patent: May 23, 2017Assignee: MERCK PATENT GMBHInventors: Markus Klein, Sven Lindemann
-
Publication number: 20160175381Abstract: The present invention relates to pharmaceutical preparations and medicaments for intraarticular administration, comprising pepstatin, and to the preparation and use thereof, in particular in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia, particularly preferably in arthrosis.Type: ApplicationFiled: July 7, 2014Publication date: June 23, 2016Applicant: Merck Patent GmbHInventors: Markus KLEIN, Ralf WODOPIA, Hans GUEHRING, Sven LINDEMANN
-
Publication number: 20150368188Abstract: The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which ADAMTS5 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.Type: ApplicationFiled: January 16, 2014Publication date: December 24, 2015Applicant: MERCK PATENT GMBHInventors: Markus KLEIN, Sven LINDEMANN
-
Publication number: 20100242567Abstract: Exemplary embodiments of the invention relate to an apparatus and method for producing untrimmed container bodies from pre-cut metal blanks. The method involves cupping a metal blank by positioning the blank against an immovable draw punch comprising an annular body having an inner surface adapted to form a redraw die and an outer surface, and drawing a periphery of the blank over the outer surface of the draw punch with an encircling draw die to form a cup having an open end, a closed end and an interior. The cup is then inverted and redrawn by forcing a redraw punch into the closed end of the cup to draw the closed end through the redraw die until the cup is inverted to form an inverted cup with a closed end supported on the punch. The inverted cup while supported on the redraw punch is passed through one or more ironing rings to lengthen the inverted cup to form an untrimmed container body having a closed end.Type: ApplicationFiled: March 25, 2010Publication date: September 30, 2010Inventors: Dubravko Nardini, Sven Lindemann, Alois Bökers